

Phase 2 Clinical Trial of Poseltinib for the Treatment of Relapsed/ Refractory Primary Central Nervous System Lymphoma

NOBO Medicine, Inc.



ONCOLOGY	Phase 2
Product Type	Small molecules
Indication	Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Target	BTK (Bruton's tyrosine kinase)-TEC (Tyrosine-protein kinase Tec) dual inhibitor
MoA(Mechanism of Action)	Poseltinib inhibits BTK, which plays critical roles in B-cell receptor signaling and TEC, which can be used as a bypass pathway for BCR signaling when BTK is inhibited, leading to reduced proliferation and survival of malignant B-cells.
Competitiveness	<ul style="list-style-type: none"> • Poseltinib has high inhibitory potency against BTK and TEC, suggesting higher efficacy. • Poseltinib has a very low inhibitory effect on CSK, which may result in fewer cardiovascular side effects. • Poseltinib shows higher brain penetration compared to other BTK inhibitors, potentially offering superior treatment efficacy for PCNSL.
Development Stage	Phase 2
Route of Administration	Oral

Any unauthorized distribution or reproduction of this material is strictly prohibited.